Healthcare >> CEO Interviews >> September 29, 2003
FUAD EL-HIBRI is Chairman and Chief Executive Officer of BioPort
Corporation since the company's inception in 1998. He developed an
acquisition strategy and led the procurement activities related to the
privatization of the Michigan Biologic Products Institute (MBPI), a
state-owned biologics production facility in Lansing, Michigan. In
September 1998, BioPort acquired MBPI, the sole manufacturer of the
anthrax vaccine in the United States. Prior to joining BioPort, Mr. El-
Hibri was a Director with Speywood Holdings, Ltd. in London, UK from
1994 to 1996. In addition to his role at BioPort, Mr. El-Hibri is
President of East West Resources Corporation in Rockville, Maryland, a
position he has held since 1990. From 1986 to 1989, Mr. El-Hibri was
Senior Associate Project Manager with Booz, Allen & Hamilton in New
York, New York. From 1982 to 1985, he was Manager, Account and
Operations Officer for Citibank, N.A., in Jeddah, Saudi Arabia. Mr. El-
Hibri attended the Yale School of Management and obtained a Master's of
Public and Private Management with an emphasis on Financial Management
and Entrepreneurship. He has a Bachelor of Arts (with honors) in
Economics from Palo Alto, California with an emphasis on International
Trade and Computer Science. Profile
what you do.
Mr. El-Hibri: BioPort is, today, the only manufacturer of licensed
vaccine for the prevention of anthrax.
